IMMX:NASDAQImmix Biopharma, Inc. analysis
Data as of Aug 28, 2026 - not real-time
- Latest price
- $14.05
- Risk: high
- 9/10High risk
Summary
Immix Biopharma, Inc. is priced at $14.05 and its moving averages line up in bullish order, the shorter sitting above the longer. The last 30 days have gained 37.1%. Relative strength is 70.4 — overbought — and the MACD signal is bullish. Watch $7.83 as support and $15.10 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 44.3% above the current price.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 90.4%, a beta of 1.59 and a maximum drawdown of 39.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 44.3% above the current price.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 90.4%, a beta of 1.59 and a maximum drawdown of 39.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top market events
- IMMX Investors Have Opportunity to Join Immix Biopharma, Inc.
- LOS ANGELES, May 21, 2026 GLOBE NEWSWIRE -- Immix Biopharma, Inc.
- LOS ANGELES, CA, Aug. 04, 2026 GLOBE NEWSWIRE -- Immix Biopharma, Inc. 'ImmixBio”, 'Company”, 'We” or 'Us” or...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- RSI at 70.4 signals overbought conditions
- Trading above the 200-day average of 8.26
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- RSI at 70.4 signals overbought conditions
- Trading above the 200-day average of 8.26
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +44.3% versus the current price
- Negative return on equity of -34.2%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-15.5
ROE-34.18%
ROA-20.52%
Debt/Equity0.44
P/B Ratio4.4
Op. Cash Flow$-38498080
Free Cash Flow$-25388076
Industry P/E30.5
Technical analysis
TrendBullish
RSI70.4
Support$7.83
Resistance$15.10
MA 20$11.78
MA 50$10.59
MA 200$8.26
MACDBullish
VolumeStable
Fear & Greed Index95.98
Valuation
Target Price$20.28
Upside/Downside44.31%
GradeFair
TypeGrowth
Risk assessment
Beta1.59
Volatility90.36%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.